Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma

NCT01693068 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01693068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01693068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Lead sponsor
EMD Serono
Phase
Phase 2
Overall status
Completed
Start date
December 5, 2012
Completion date
October 24, 2016
Enrollment
194 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

n-ras mutated locally advanced or metastasis malignant cutaneous melanoma